Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) released its quarterly earnings data on Friday. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01, Zacks reports.

Sana Biotechnology Stock Down 3.8 %

NASDAQ:SANA traded down $0.11 on Monday, reaching $2.89. The company’s stock had a trading volume of 1,981,002 shares, compared to its average volume of 2,151,145. The firm has a market cap of $642.93 million, a price-to-earnings ratio of -2.29 and a beta of 1.44. Sana Biotechnology has a 12-month low of $2.76 and a 12-month high of $12.00. The stock has a 50 day moving average price of $4.21 and a 200 day moving average price of $5.77.

Insider Activity at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 31.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Sana Biotechnology in a research report on Monday. Finally, Citigroup lifted their target price on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.